The Trump administration will work with Gilead (GILD) Sciences and The Global Fund to Fight AIDS, Tuberculosis and Malaria to provide an HIV prevention drug to up to 2 million people in low- and middle-income countries, STAT’s Ed Silverman and Jason Mast report. While the effort was first announced in 2024, the administration began to drastically cut foreign aid.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead’s Promising Phase 3 Study on Sacituzumab Govitecan for Lung Cancer
- Ideaya Biosciences enrolls first patient in IDE397 trial
- Positive Long-Term Outlook for Gilead Sciences’ PrEP Franchise Driven by Descovy’s Performance and Favorable Policy Environment
- These 3 “Strong Buy” Value Stocks Have over 10% Upside, According to Analysts – 9/3/2025
- Gilead Sciences Advances Lung Cancer Treatment with Novel Drug Combinations